Compounders Research Compare

Olema Pharmaceuticals, Inc.(OLMA)

Biotechnology · San Francisco, CA

$7.94-0.31 (-3.76%)

Delayed quote: Oct 6, 2026, 2:50 PM EDT

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.

San Francisco, CA

150 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Sean Bohen

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T18:52:31.211Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:52:31.211Z.

Quote observation: 2026-10-06T18:50:09.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 693,538,920
Total debt · period ending 2026-06-30: 660,000
Cash · period ending 2026-06-30: 48,599,000
TTM free cash flow · period ending 2026-06-30: -164,737,000

FMP input reference: 4efcc2f75e7b9d1a3dd193370b83b229becf15f1f7fcdbde4bbae966de3ea950

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

OLMA EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

OLMA Competitors' EV/FCF Ratio

Olema Pharmaceuticals, Inc.

Current

Market Cap

$693.54M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Anteris Technologies Global Corp.

Market Cap

$693.75M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Wave Life Sciences Ltd.

Market Cap

$691.64M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Verastem, Inc.

Market Cap

$687.69M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Solid Biosciences Inc.

Market Cap

$684.45M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Collegium Pharmaceutical, Inc.

Market Cap

$712.89M

EV/FCF Ratio

4.39x

TTM Avg

7.12x

3Y Avg

7.74x

5Y Avg

9.53x

Annexon, Inc.

Market Cap

$672.57M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

4D Molecular Therapeutics, Inc.

Market Cap

$669.66M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Avalo Therapeutics, Inc.

Market Cap

$716.48M

EV/FCF Ratio

N/A

TTM Avg

1185.88x

3Y Avg

1179.74x

5Y Avg

1179.74x

Helus Pharma Inc.

Market Cap

$669.43M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Olema Pharmaceuticals, Inc. (OLMA)	$693.54M	N/A	N/A	N/A	N/A
Anteris Technologies Global Corp. (AVR)vs ›	$693.75M	N/A	N/A	N/A	N/A
Wave Life Sciences Ltd. (WVE)vs ›	$691.64M	N/A	N/A	N/A	N/A
Verastem, Inc. (VSTM)vs ›	$687.69M	N/A	N/A	N/A	N/A
Solid Biosciences Inc. (SLDB)vs ›	$684.45M	N/A	N/A	N/A	N/A
Collegium Pharmaceutical, Inc. (COLL)vs ›	$712.89M	4.39x	7.12x	7.74x	9.53x
Annexon, Inc. (ANNX)vs ›	$672.57M	N/A	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$669.66M	N/A	N/A	N/A	N/A
Avalo Therapeutics, Inc. (AVTX)vs ›	$716.48M	N/A	1185.88x	1179.74x	1179.74x
Helus Pharma Inc. (HELP)vs ›	$669.43M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics